EBM --- Journal Reading

1. EBM --- Journal Reading Presenter：顏志維 Date：2005/10/17

2. Users’ Guides to the Medical LiteratureⅡ. How to Use an Article About Therapy or PreventionA. Are the Results of the Study Valid ？ Gordon H. Guyatt, MD. MSc; David L. Sackett, MD. MSc; Deborah J. Cook, MD. MSc; for the Evidence-Based Medicine Working Group JAMA; Dec 1, 1993; 270, 21

3. Background • A 19 year-old woman with systemic lupus erythematosus had renal disease. • A year ago  Cr 140 micromoles/ litre • Six months ago 180 • A week before 220 • Anti-autoimmune agent: prednisone, and over the last six months, cyclophosphamide

4. How did the problem generate? • Consider a trial of plasmapheresis because the rise of creatinine. • Plasmapheresis can reduce the level of the antibodies responsible for the nephritis • But I don’t know if any randomized clinical trials available.

5. Helpful articles are related to • Patients with severe lupus that threatens renal function and who are, already receiving immunosuppressive agents. • Plasmapheresis must be compared with a control management strategy, and patients must be randomized to receive or not receive the plasmapheresis. • Finally, the article must report clinically important outcomes, such as deterioration in renal function.

6. Search • In software program "Grateful Med" • Use mash terms including: • lupus nephritis, plasmapheresis, randomized controlled trial • Restrict to English-language articles. • A total of three papers

7. The most likely useful one… • A controlled trial of plasmapheresis therapy in severe lupus nephritis. • 46 patients received a standard therapeutic regimen of prednisone and cyclophosphamide • 40 patients received standard therapy plus plasmapheresis

8. And… • Trend toward a greater proportion of the plasmapheresis-treated patients dying (20% versus 13%) or developing renal failure (25% versus 17%). • I wonder, however, whether the study could have led to an inaccurate or biased outcome.

11. Was follow-up complete? • Every patient who entered the trial should be accounted for at its conclusion. • Gaining Bias when more lost f/u objects. • We can also accept: all patients lost from the treatment group did badly, and all lost from the control group didwell, and then recalculating the outcomes.

12. Was the assignment of patients to treatment randomized? • Clinical outcomes result from many causes, and treatment is just one of them: underlying severity of illness, the presence of co-morbid conditions, and a host of other prognostic factors (unknown as well as known) often swamp any effect of therapy. • It turns out that studies in which treatment is allocated by any method other than randomization tend to show larger.

13. RCTs usually bring surprise • Here are some examples: • Extracranial-intracranial bypass make patients worse off in the immediate post-surgical period • Steroids may increase mortality in patients with sepsis • Steroid injections do not ameliorate facet-joint back pain • Plasmapheresis does not benefit patients with polymyositis

14. Were patients analyzed in the groups to which they were randomized? • Patients sometimes forget to take their medicine or even refuse their treatment altogether, they should be excluded from analyses for efficacy? Not so • Non-compliant patients have worse prognosis than those who took their medication as instructed, even when their medications were placebos!

15. RCT的精髓 • This principle of attributing all patients to the group to which they were randomized results in an "intention-to-treat" analysis. • This strategy preserves the value of randomization: prognostic factors that we know about, and those we don't know about, will be, on average, equally distributed in the two groups, and the effect we see will be just that due to the treatment assigned.

16. Were patients, their clinicians, and study personnel "blind" to treatment? • Unblind：opinions can systematically distort both the other aspects of treatment, and the reporting of treatment outcomes；measuring outcomes including marginal findings or differential encouragement.

17. About blinding • The best way is double-blinding • Placebo should be same in appearance, taste and texture but lacking the putative active ingredient. • Whether investigators have minimized bias by blinding those who assess clinical outcomes.

18. Were the groups similar at the start of the trial? • Randomization doesn't always produce groups balanced for known prognostic factors. Esp: when the groups are small

19. Aside from the experimental intervention, were the groups treated equally? • Interventions other than the treatment under study, when differentially applied to the treatment and control groups, often are called "cointerventions". • Cointerventions are described in the methods section and documented to be infrequent occurrences in the results.

20. Back to the article • One patient assigned to standard therapy was lost to follow-up. • Not blinded • The two groups were comparable • Described the concept of strength of inference, but not “yes” or “no” .